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Introduction
End-stage renal disease (ESRD) patients treated by chronic dialysis have a worryingly high mortality, only comparable with aggressive forms of cancer. Although in the last decade numerous progresses were made in the management of dialysis patients, morbidity and mortality rates remain high, approaching 15-20% annually [1] . Almost 40% of this mortality is attributable to cardiovascular (CV) disease [2] . Unfortunately, there seems to be little hope in sight for improvements since almost all large, randomized controlled trials have persistently shown no survival benefit from several "new" treatment approaches: use of statins [3] , ESA's [4] , vitamin D or cinacalcet [5, 6] , antioxidant or homocysteine lowering therapies [7] , prolonged or more frequent dialysis sessions [8] or convective therapies [9] .
Numerous explanations were found for these disappointing results: underpowered studies, selection of 'healthier' patients for trials, better survival due to higher intensity of care during trial, high drop-out rates, and competing risks for mortality. Therefore, recognizing which patients are at the greater risk of cardiac mortality and could benefit from targeted management remains the best available approach for reducing the impressive mortality.
Cardiac biomarkers are a useful target for risk stratification. Although biomarkers such as albumin [10] or C reactive protein or natriuretic peptides [11, 12] have already been validated for predicting overall and cardiovascular mortality in CKD patients, the optimal biomarker and/or combination of biomarkers for risk stratification remains uncertain.
Cardiac troponins are frequently elevated even in the absence of acute coronary syndrome in chronic kidney disease (CKD) and in dialysis populations [13] . Classical cardiac troponins T (cTnT) and I (cTnI) have been corroborated with all-cause mortality or cardiac ischemia in stable dialysis cohorts [14] . The fifth-generation high sensitivity cardiac troponin T (hs-cTnT) test provides a high assay precision at the 99th percentile of the normal reference population. In the general population it has improved the detection, especially in the early phase of myocardial infarction; additionally, it is able to predict more accurately the risk for future cardiovascular events and death compared with conventional assays [15] .
The clinical utility of hs-cTnT in a stable dialysis cohort is still unclear. Hs-cTnT levels are strongly associated with left ventricular hypertrophy in a large dialysis cohort [16] , and a predictor of death in several recent reports [17] [18] [19] . However, the utility of a combination of hs-cTnT with natriuretic peptides for recognizing patients at high risk for major CV events or death has still not been explore.
In this context we performed a prospective observational study in a stable dialysis cohort to determine the utility of hs-cTnT alone versus hs-cTnT in combination with NTproBNP for predicting death and fatal or non-fatal major CV events.
Material and Methods

Study population
All prevalent patients undergoing chronic HD treatment for at least 3 months in a single unit were assessed for eligibility for inclusion (prevalent cross-sectional cohort approach). Patients fitted with a cardiac pacemaker (N=5), chronic atrial fibrillation (N=20), lower limb amputation (N=6), poor echocardiographic window (N=3), non-functioning arterio-venous fistula (AVF) (N=5), less than 3 months dialysis vintage (N=10) or refusal to participate (N=12) were excluded from the study. All remaining patients (N=98) were treated uniformly with 12 hours of dialysis/week, using high-flux polysulphone membranes (FX60), a mean Voroneanu/ Siriopol/ Nistor/ Apetrii/ Hogas/ Onofriescu/ Covic: Cardiac Biomarkers in Dialysis blood flow of 400 ml/min and conductivity 135 ms. All patients signed an informed consent, and ethical approval was obtained from the Hospital and University ethical committee, as per country protocol.
Demographic, clinical and biochemical parameters
The following parameters were recorded: age, gender, body surface area, diabetes, residual diuresis, interdialytic weight gain (mean of the last 6 HD sessions). Additionally, eKt/V was calculated using the Daugirdas formula [19] . Time spent on HD (HD vintage), and other dialysis modalities preceding HD (PD, transplant) were noted in months.
The following biochemical parameters were recorded: serum hemoglobin, albumin, urea, creatinine, parathormone level, and calcium and serum inorganic phosphates. Blood samples for hs-cTnT assay were collected before the midweek HD session; the determination was made using a fifth-generation electrochemiluminescence assay (Elecsys, Cobas e411 analyzer, Roche Diagnostics). According to the manufacturer of the assay, for hs-cTnT the stated limit of detection is 5 ng/L, the analytical range is 3-10 000 ng/L, and the upper reference limit (99th percentile) in the normal population is 14 ng/L.
NT-proBNP in serum samples were collected before the midweek HD session and were analyzed centrally using the Roche Elecsys® kit, an electro-chemiluminescence 'sandwich' immunoassay based on polyclonal antibodies against NT-proBNP.
Congestive heart failure was defined according to the New York Heart Association (NYHA) classification. Ischemic heart disease was defined based on clinical and EKG characteristic alterations or angiography. Blood pressure assessment was performed pre-HD, after 30 min. of recumbency; the last BP value of a three measurements series was used throughout the study. During the HD session, BP was recorded every 30 minutes.
Hydration status and body composition bioimpedance-derived measurements.
Measurements of hydration and body composition were performed using a multi-frequency bioimpedance device (BCM®). This device measures the impedance spectroscopy at 50 frequencies. Measurements were performed before the start and 30 min after the end of the HD treatment. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW), and the total body water (TBW) are calculated [20] . Absolute fluid overload (AFO) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RTH) is defined as the AFO to ECW ratio.
Echocardiography and arterial stiffness assessment.
All patients had a baseline echocardiography. Echocardiographic evaluations were made in each patient before the midweek HD session. All echocardiographic measurements were carried out according to the recommendations of the American Society of Echocardiography [21] by an independent observer. Applanation tonometry was done with a SphygmoCor device (AtCor Medical, Westmead, Sydney, Australia). The PWV was computed from carotid and femoral artery waveforms recorded consecutively, using an electrocardiogram-gated signal and anthropometric distances. All measurements were done before the midweek HD session.
Follow-up and outcomes
All patients were enrolled in study in june-september 2011. All patients were followed at regular dialysis sessions for a pre-specified period of 24 months (until september 2013) or until death; the main outcome was death from all cause. Fatal or non-fatal major cardiovascular events were recorded in the EUCLID® database.
Statistics
Statistical significance of differences was tested with the ANOVA test for continuous and normally distributed parameters, the Mann Whitney U test for non-normally distributed parameters or Fisher's exact test for categorical parameters. The cut-off values for NT proBNP and hs-cTnT for overall mortality was calculated using receiver operating characteristic (ROC) analysis ROCs and the area under the curve (AUC). Kaplan-Meier and Cox regression analysis were used to investigate the prognostic value of these two biomarkers for predicting mortality, analyzing hs-cTnT and NT-proBNP as a categorical variable. In a Cox proportional hazards model, NT-proBNP, hs-cTnT, and baseline parameters (age, gender, presence of diabetes mellitus, cardiovascular diseases, hepatitis), together with laboratory parameters, blood pressure, arterial stiffness, hydration status were included to assess the relative risk of mortality. These factors were used first in a univariate model. All parameters showing an association with mortality at a p value <0.05 were included in a multivariate model; To avoid the problem of over fitting due to the low number of incident outcomes, we performed bootstrapping validation, in order to determine the confidence intervals for estimating β in the Cox proportional hazard regression.
To determine the potential utility of simultaneous hs-cTnT and NTproBNP assessment, we divided the sample into four groups based on hs-cTnT and NTproBNP cut-off points: group 1-NT-proBNP < 14275 pg/ ml; hs-cTnT < 69.48 ng/l; group2 -NT proBNP < 14275 pg/ml; hs-cTnT > 69.48 ng/l; group 3 -NT proBNP > 14275 pg/ml; hs-cTnT < 69.48 ng/l and group 4 NT proBNP > 14275 pg/ml, hs-cTnT > 69.48 ng/l.
All statistical analyses were performed using SPSS version 19.0. A p value of 0.05 was considered significant.
Results
Demographic characteristics are presented in Table 1 : mean age of participants was 61.4 ± 13.9 years, 50% were women; the dialysis vintage was 112.2 ± 13.5 months; almost 68% of the patients were hypertensives and 38% had a previous heart failure hospitalization. The median hs-cTnT level was 44.7 ng/l (table 1). Using this high sensitivity assay, 95 participants (94%) had hs-cTnT above the 99th percentile of the normal population (14 ng/l, see methods). Levels of hs-cTnT were correlated with patients' age (r = 0.207; p = 0.041), dialysis vintage (r = 0.200; p = 0.05), and NT-proBNP levels (r = 0.339, p = 0.0001). Men tended to have higher values than women (73.2 versus 45.8 ng/l; p = 0.04). Hypertensive patients also had significantly higher levels of hs-cTnT (74.1 versus 48.7 ng/l in normotensives; 
Survival analysis
Patients in the study were monitories for 24 months; during this period 16 deaths (16.3%) were recorded. Cardiac death was recorded in 9 patients; 6 patients developed sudden cardiac death, while 3 patients had an acute coronary syndrome. The main cause of non-cardiovascular death was infection-related (7 patients).
There was a higher baseline level of NT-proBNP (26354.5 vs 5896.0 pg/ml; p = 0.005) and of hs-cTnT (71.5 vs 37.4 ng/l; p = 0.007) in patients who died compared with survivors. Additionally, deceased patients were older (65.5 vs 53.4 yrs; p = 0.002) and had higher arterial stiffness in comparison with patients who survived (table 1). There was no difference in hydration status between survivors and non-survivors (see table nr. 2). Additionally, there was no difference in hydration status between survivors and non-survivors, in patients with previous history of heart failure hospitalization (see table nr.2).
N-proBNP and hs-cTnT as predictors of mortality
According to the ROC curves, the cut-off point for NT-proBNP as a predictor of mortality was 14275 pg/ml, with a sensitivity of 68.7% and a specificity of 79.3%. The area under the curve was 0.722 (p = 0.003). The cut-off point for hs-cTnT as a predictor of mortality, according to the ROC curves, was 69.43 ng/l, with a sensitivity of 68% and a specificity of 79%. The area under the curve was 0.618 (p = 0.04). The area under the curve for both NT-proBNP and hs-cTnT was 0.756 (p = 0.001). Both NT-proBNP and the combination (NTproBNP and hs-cTnT) exhibited good prognostic accuracy for survival, with AUC values of 0.722 and 0.756, respectively.
Kaplan Meier analysis showed that all cause mortality was significantly higher in patients with NT-proBNP >14275 pg/ml (p = 0.002) and in patients with an hs-cTnT >69.43 mg/dl (see figure nr 1a and 1b) . 
Univariate and multivariate survival analysis
Univariate Cox regression analysis, including traditional and non-traditional risk factors, showed the following items to be predictive for death, in this HD population: NT-proBNP >14275 pg/ml, hs-cTnt >69.43 ng/l, age, ischemic heart disease and arterial stiffness (table  3) . In multivariate analysis, only NT-proBNP, age and ischemic heart disease remained independent predictor of mortality, whereas hs-cTnT lost its predictive significance -( Table 3) .
As a continuous variable, NT proBNP but not hs-cTnT predicted death from all cause mortality in univariate Cox analysis (HR = 2.16; 95% CI = 1.27-3.67). In multivariable analysis, this biomarker remains an independent predictor of mortality (see table 4 ).
Nine deaths were attributing to CV events. Univariate analysis showed that NT-proB-NP >14275 pg/ml, hs-cTnt >69.43 ng/l, age, ischemic heart disease were predictors for CV death. In multivariate analysis, only NT-proBNP and ischemic heart disease remained independent predictor of mortality, whereas hs-cTnT lost its predictive significance (see table nr.5).
Combined analysis of the biomarkers for mortality
To determine the potential utility of simultaneous hs-cTnT and NT-proBNP assessment, we divided the samples into four groups based on hs -cTnT and NT-proBNP cut-off points (see table 3 . In contrast, both groups with high NT-proBNP levels (with normal hs-cTnT or with high hs-cTnT) had a significant higher risk of overall mortality (HR = 4.78; p = 0.033 and HR = 6.15; p = 0.005, respectively) compared with the reference group (see table 6 and figure 2) .
However, the addition of hs-c TnT to NTproBNP did not improve significantly the predictive power of NT-proBNP alone (HR = 6.15 versus HR = 4.78; p = 0.338).
Discussion
This observational prospective pilot study provides a comprehensive analysis of the prognostic value of high-sensitivity cTnT alone or in combination with NT-proBNP, as a predictor of mortality, over a 2-year period, in a stable cohort of chronic HD patients. We showed that hs-CTnT, in contrast to NT proBNP is not a valuable biomarker for predicting Table 6 . COX regression analysis based on cutt-off levels of hs-cTnT and NTproBNP Table 5 . Univariate and multivariate COX regression analysis (CV mortality)
Voroneanu/ Siriopol/ Nistor/ Apetrii/ Hogas/ Onofriescu/ Covic: Cardiac Biomarkers in Dialysis mortality; additionally, we found that the combination of these two biomarkers did not improve risk stratification for death above and beyond a model including NT-proBNP alone.
Plasmatic levels of natriuretic peptides in both general and renal populations are tightly correlated with all-cause mortality, and especially with cardiovascular mortality [12] . Our data reconfirm the prognostic value of NT-proBNP for subsequent mortality risk in HD patients.
Similar to previous studies conducted in CKD and dialysis patients [17] [18] [19] , we found a high proportion of patients in our cohort (95%) with a hs-cTnT concentration above the 99th percentile of the normal population (14 ng/l). In contrast, the older studies, using the classical cTnT assay, reported only 15-45% of patients having increased concentration [13, 22] . This higher sensitivity is associated with a better predictive value of mortality in general population [15, 23] .
The prognostic value of classical troponins, in dialysis patients, was demonstrated by numerous studies including a recent meta-analysis [14] . In almost 4000 patients, elevated classical TnT (>0.1 ng/mL) was significantly associated with increased all-cause mortality (RR = 2.64; 95%CI = 2.17 to 3.20). The ability of hs-cTnT to predict all cause and CV mortality in hemodialysis patients has been examined in few studies. Hassan et al. [19] demonstrated an increased risk for myocardial infarction and for general mortality with increasing hs troponin quartiles in 393 dialysis patients (including 275 on hemodialysis). Similarly, Artunc et al. [18] reported that hs-cTnT concentrations above 38 pg/mL were associated with a 5-fold risk of death, during a follow-up period of almost two years, in a 239 hemodialysis cohort. We showed, in our observational prospective study, that hs-cTnT is an effective marker for survival in univariate Cox analysis. Patients with hs-cTnT above 69.43 pg/ml had a 3.3-fold increased risk of death; the predictive value was lost in multivariate analysis, when adjusting for confounders. Similar data are reported by McGill et al. [24] : in a stable dialysis cohort, after a median 30 months of follow-up, NT-proBNP was the only biomarker predictive for all cause mortality and not hs-cTnT. Moreover, in the same study, they determined both classical and hs-cTnT in 143 patients and followed these patients during 3.9 years. The AUC showed that hs-TnT improves the prediction for all-cause mortality as compared to the fourth generation TnT (0.760 vs. 0.746).
Comparison of the diagnostic performance of NT-proBNP with classical or with hs-cTnT, in dialysis patients
There are several studies that compared directly the prognostic value of NT-proBNP and classical troponins in HD populations, with strikingly different results. Sommerer et al. [25] found in 134 stable asymptomatic patients that both NT-proBNP and cTnT are independent predictors of the composite end-point of death and CV events. Fernandes Reyes et al [26] , in a small dialysis cohort (58 pts) found that NT-proBNP level was strongly correlated with cTnT and cTnT was the best predictor of death. Apple et al. [27] found in 399 hemodialysis patients that both cTnT and cTnI are independent predictors of all cause mortality, but NTproBNP, despite being elevated in nearly 99% of the patients. In contrast, Satyan et al. [28] showed in 150 asymptomatic dialysis patients that NT-proBNP is strongly related with all cause and CV mortality; adding troponin did not improve the prognostic value compared with NT-proBNP alone.
The diagnostic performance of NT-proBNP compared to the new hs-cTnT was described until now in only one previous study. McGill et al. [24] , found in 143 dialysis patients that NT-proBNP and albumin had a strong predictive value for all-cause mortality at 30 months of follow-up; however, after a median follow-up of 46.7 months the new hs-cTnT assay was the only cardiac biomarker predictive of all-cause mortality, suggesting that NT-proBNP is a better predictor for early mortality and troponin for long-term mortality. Similar data were found in our study: at 24 months of follow-up, NT-proBNP and not hs-cTnT was the only predictor of overall mortality risk. The diagnostic performance of the combination of hs-cTnT and NT proBNP for risk stratification in dialysis In general population combination of these two biomarkers improves substantially the predictive accuracy. In a large heart failure cohort, de Antonio et al. [29] found that both NTproBNP and hs-cTnT were predictors of mortality, but the combination of both biomarkers was associated with substantially higher accuracy, compared with either biomarker alone, reaching a very significant HR of 7.42. In another large (3800 pts) diabetes cohort, the combination of NT-proBNP and hs-cTnT also greatly improved the accuracy with which the risk of cardiovascular events or death could be estimated [30] . The addition of either marker improved 5-year risk classification for cardiovascular events (net reclassification index in continuous model, 39% for NT-proBNP and 46% for hs-cTnT).
For the first time, we used the combination of NT-proBNP and hs-cTnT for predicting mortality risk in HD patients and found that hs-CTnT is not an independent contributor to the survival prediction. The addition of hs-CTnT to a NT proBNP prediction model failed to be associated with a significantly better risk discrimination, as compared to NT-proBNP alone.
Limitations
The limitations of our study were the relatively small sample size but with 2-years period of follow-up. Our study population had a long-lasting HD treatment; this does not represent a common situation in daily dialysis practice and results cannot be generalized for all dialysis patients. Although albumin and diabetes have been considered as survival predictors, our study included a small number of patients with diabetes and a small number of patients with low albumin level, thus precluding a possible statistical effect of these parameters. Levels of hs-cTnT have been measured from frozen rather than fresh samples. There is little information about long-term stability of frozen hs-cTnT. The deceased groups of our patients were older and with higher percentage of ischemic heart disease compared with the survivor group. However, the prognostic power of NT proBNP remains statistically significant after adjusting for ischemic heart disease.
Conclusions
NT-proBNP and not hs-cTnT is a predictor of all-cause mortality in stable, long-term dialysis patients, at 24 months of follow-up. The combination of NT-proBNP and hs-TnT did not improve the prognostic accuracy compared to NT-proBNP alone.
Whether or not these biomarkers should be routinely measured in ESRD patients still remains to be answered. Future studies will hopefully address the significance of sequential measurement of these biomarkers in ESRD patients and the effects of therapeutic interventions based on biomarker levels.
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